z-logo
open-access-imgOpen Access
Functional rescue in a mouse model of congenital muscular dystrophy with megaconial myopathy
Author(s) -
Ambreen Sayed-Zahid,
Roger B. Sher,
Stacey J. Sukoff Rizzo,
Laura Anderson,
Kathryn E Patenaude,
Gregory A. Cox
Publication year - 2019
Publication title -
human molecular genetics online/human molecular genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.811
H-Index - 276
eISSN - 1460-2083
pISSN - 0964-6906
DOI - 10.1093/hmg/ddz068
Subject(s) - muscular dystrophy , myopathy , transgene , phenotype , biology , skeletal muscle , itga7 , genetic enhancement , dystrophy , downregulation and upregulation , muscle disorder , genetics , cancer research , gene , medicine , endocrinology
Congenital muscular dystrophy with megaconial myopathy (MDCMC) is an autosomal recessive disorder characterized by progressive muscle weakness and wasting. The observation of megamitochondria in skeletal muscle biopsies is exclusive to this type of MD. The disease is caused by loss of function mutations in the choline kinase beta (CHKB) gene which results in dysfunction of the Kennedy pathway for the synthesis of phosphatidylcholine. We have previously reported a rostrocaudal MD (rmd) mouse with a deletion in the Chkb gene resulting in an MDCMC-like phenotype, and we used this mouse to test gene therapy strategies for the rescue and alleviation of the dystrophic phenotype. Introduction of a muscle-specific Chkb transgene completely rescues motor and behavioral function in the rmd mouse model, confirming the cell-autonomous nature of the disease. Intramuscular gene therapy post-disease onset using an adeno-associated viral 6 (AAV6) vector carrying a functional copy of Chkb is also capable of rescuing the dystrophy phenotype. In addition, we examined the ability of choline kinase alpha (Chka), a gene paralog of Chkb, to improve dystrophic phenotypes when upregulated in skeletal muscles of rmd mutant mice using a similar AAV6 vector. The sum of our results in a preclinical model of disease suggest that replacement of the Chkb gene or upregulation of endogenous Chka could serve as potential lines of therapy for MDCMC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here